Dr. Walid Al Zaher

Dr. Walid Zaher is currently the Chief Research Director at G42 Healthcare and Vaccine Trial Lead at the ongoing Phase 3 trial of inactivated vaccine against COVID-19.

He graduated with Bachelor of Medicine and Surgery from Saudi Arabia with a residency training in obstetrics and gynecology, followed by Master’s degrees in medical education, anatomy & embryology and bioscience technology. He has also attained a PhD in regenerative Medicine from Denmark, along with laser-medicine training at Harvard-MGH (Boston-USA).

Before joining G42 Healthcare, Dr. Walid was the Corporate Group Clinical Research & Innovation Director at Abu Dhabi Health Services Company (SEHA). Prior his stint in the UAE, he was the General Director of the College of Medicine Research Centers at King Saud University (Riyadh, Saudi Arabia).

He has been a consultant for Saudi 2020 National Biotechnology and Infectious Disease plan and an assistant professor of regenerative medicine and stem cells.

Currently, he is also an adjunct Associate Professor at the College of Medicine and Health Sciences at United Arab Emirates University with more than 30 ISI publications in reputed journals including Nature and Stem Cells.